Subscribe To
ETNB / 89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study
ETNB News
By Seeking Alpha
October 26, 2023
89bio's Low Price Presents An Opportunity
89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive more_horizontal
By GlobeNewsWire
October 17, 2023
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
SAN FRANCISCO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and more_horizontal
By The Motley Fool
October 10, 2023
Why Shares of 89bio Plummeted on Tuesday
89bio is a clinical-stage biotech company. It focuses on treatments for liver and cardiometabolic diseases. more_horizontal
By Proactive Investors
August 28, 2023
89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeutic
Analysts at UBS have initiated coverage on 89bio (ETNB) with a ‘Buy' rating and a US$36 price target, representing an upside of about 117.5% from th more_horizontal
By Seeking Alpha
August 10, 2023
89bio, Inc.: A Big Bet On NASH
89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-li more_horizontal
By Market Watch
June 13, 2023
89bio shares rise as analysts see improved outlook for NASH treatments
Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the more_horizontal
By Zacks Investment Research
May 29, 2023
89BIO (ETNB) Just Overtook the 20-Day Moving Average
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed a more_horizontal
By Seeking Alpha
May 28, 2023
89bio: Great Prospects After Excellent Phase 2 Data
ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now. more_horizontal